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ABSTRACT
Study queStion
How effective is supported computerised cognitive 
behaviour therapy (cCBT) as an adjunct to usual 
primary care for adults with depression?
MethodS
This was a pragmatic, multicentre, three arm, parallel 
randomised controlled trial with simple 
randomisation. Treatment allocation was not blinded. 
Participants were adults with symptoms of depression 
(score ≥10 on nine item patient health questionnaire, 
PHQ-9) who were randomised to receive a 
commercially produced cCBT programme (“Beating 
the Blues”) or a free to use cCBT programme 
(MoodGYM) in addition to usual GP care. Participants 
were supported and encouraged to complete the 
programme via weekly telephone calls. Control 
participants were offered usual GP care, with no 
constraints on the range of treatments that could be 
accessed. The primary outcome was severity of 
depression assessed with the PHQ-9 at four months. 
Secondary outcomes included health related quality 
of life (measured by SF-36) and psychological 
wellbeing (measured by CORE-OM) at four, 12, and 24 
months and depression at 12 and 24 months.
Study anSwer and liMitationS
Participants offered commercial or free to use cCBT 
experienced no additional improvement in depression 
compared with usual GP care at four months (odds 
ratio 1.19 (95% confidence interval 0.75 to 1.88) for 
Beating the Blues v usual GP care; 0.98 (0.62 to 1.56) 
for MoodGYM v usual GP care). There was no evidence 
of an overall difference between either programme 
compared with usual GP care (0.99 (0.57 to 1.70) and 
0.68 (0.42 to 1.10), respectively) at any time point. 
Commercially provided cCBT conferred no additional 
benefit over free to use cCBT or usual GP care at any 
follow-up point. Uptake and use of cCBT was low, 
despite regular telephone support. Nearly a quarter of 
participants (24%) had dropped out by four months. 
The study did not have enough power to detect small 
differences so these cannot be ruled out. Findings 
cannot be generalised to cCBT offered with a much 
higher level of guidance and support.  
what thiS Study addS
Supported cCBT does not substantially improve 
depression outcomes compared with usual GP care 
alone. In this study, neither a commercially available 
nor free to use computerised CBT intervention was 
superior to usual GP care.
Funding, CoMpeting intereStS, data Sharing 
Commissioned and funded by the UK National Institute 
for Health Research (NIHR) Health Technology 
Assessment (HTA) programme (project No 06/43/05).  
The authors have no competing interests. Requests for 
patient level data will be considered by the REEACT 
trial management group
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Introduction
Depression is one of the most common reasons for GP 
consultations, and its associated personal and eco-
nomic burden is considerable.1  While antidepressants 
remain an important treatment option, many patients 
and healthcare professionals would like to access psy-
chological therapy as an alternative or adjunct to drug 
treatment.2 3
Cognitive behaviour therapy (CBT) has emerged as a 
leading evidence supported form of brief psychological 
therapy for people with depression.4 5  Demand for CBT, 
however, cannot be met from existing therapist 
resources.6  One alternative to therapist delivered CBT is 
the provision of therapy through a computer.7  Several 
interactive programmes have been developed that 
enable CBT to be delivered by computer. National Insti-
tute of Health and Care Excellence (NICE) guidelines 
recommend the provision of computerised CBT (cCBT) 
WhAT IS AlReAdy knoWn on ThIS TopIC
There is an increasing interest in the delivery of cognitive behaviour therapy (CBT) 
through computers (cCBT), which is a potentially effective and efficient mode of 
delivery for the large numbers of people with depression in primary care
cCBT is endorsed in evidence supported NICE guidelines and forms a component of 
Improving Access to Psychological Therapy services, but research has generally 
been conducted in specialist centres and by researchers who have also developed 
the programmes
WhAT ThIS pApeR AddS
This study was a large independent evaluation of the effectiveness of commercial 
and free to use cCBT in UK primary care
Despite the provision of telephone support to use the cCBT programmes, there was 
limited uptake by people with clinical depression
Commercially developed and free to use cCBT programmes conferred little or no 
clinical benefit when offered in addition to usual primary care for depression
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as an initial lower intensity treatment for depression as 
part of a “stepped care” approach in primary care,5  and 
forms one of a range of psychological interventions 
offered in many Improving Access to Psychological 
Therapy (IAPT) services.8  If effective, such programmes 
have the potential to expand access to psychological 
therapy in primary care and could represent an efficient 
non-pharmacological intervention for depression or 
adjunct to pharmacological treatments.9
For those who decide to use (or commission the pro-
vision of) cCBT there are several interactive internet 
based products; some commercially produced and oth-
ers free to use.7 In the first category, commercial prod-
ucts have been marketed to bodies such as the NHS. The 
alternative free to use products comprise a range of pro-
grammes that have been developed by the public sector 
or by research institutes. These can be accessed at no 
direct cost to healthcare providers or patients.
Research evidence in support of cCBT (both commer-
cial and free to use) has generally been supportive,7 9 10 
with claims of effectiveness comparable with that seen 
in CBT delivered by a therapist.9 11  Meta-analysis of the 
effectiveness of cCBT has shown larger effect sizes 
where a level of professional support or guidance is 
offered to accompany the computer mediated treatment 
programme.12  A concern is the degree to which patients 
find it acceptable to receive psychological therapy 
through a computer rather than from a trained thera-
pist. Many patients offered cCBT do not access the mate-
rial or make minimal use of it.13  Non-randomised 
studies have also shown higher dropout rates14  than 
those seen in summaries of developer led trials.9  There 
has been limited qualitative research into the accept-
ability of cCBT.14  Previous systematic reviews have also 
highlighted the need for studies that recruit partici-
pants in primary care settings (rather than academic 
centres or secondary care) and the need for longer term 
follow-up beyond one year and use a standardised diag-
nostic assessment.12
A United Kingdom technology appraisal of computer-
ised treatments published in 2006 gave cautious sup-
port to the use of a commercially developed cCBT 
package for depression but also recommended that an 
independent evaluation of the acceptability and effec-
tiveness of cCBT be undertaken as a matter of priority.7 
In 2008 the REEACT trial (Randomised Evaluation of 
the Effectiveness and Acceptability of Computerised 
Therapy) was commissioned by the UK National Insti-
tute of Health Research (NIHR) Health Technology 
Assessment (HTA) programme as an independent eval-
uation. In 2009 the earlier technology appraisal was 
superseded when cCBT, meeting the stated quality cri-
teria, was generically endorsed in NICE clinical guide-
lines for the initial treatment of depression.
We investigated the effectiveness and acceptability of 
supported cCBT as an adjunct to usual GP care for 
depression and the relative effectiveness of free to use 
and commercially developed packages. We will report 
elsewhere the results of a concurrent process evalua-
tion using qualitative methods of the acceptability of 
supported cCBT.
Methods
The REEACT study was a pragmatic, multicentre, three 
arm, parallel, randomised controlled trial. Adults pre-
senting with symptoms of depression in primary care 
were randomised 1:1:1 to receive either usual care from 
their GP or usual care from their GP plus one of two 
interventions: a commercially produced cCBT interven-
tion (“Beating the Blues”) or a free to use cCBT interven-
tion (MoodGYM). Each of these products had previously 
been endorsed in a technology appraisal7  and NICE 
guidelines5  and had been shown to be effective in 
developer led trials.15 16 Appendix 1 shows the trial pro-
tocol.
recruitment of participants and baseline 
assessment
We evaluated the use of supported cCBT in the broad 
population of patients in primary care who were eligi-
ble and appropriate for this intervention. We set a min-
imum eligibility criterion based on a widely used 
measure of depression severity (score ≥10 on the nine 
item patient health questionnaire, PHQ-9) as this has 
been well validated against standardised criteria17  and 
is also the measure commonly used to assess depres-
sion and to inform treatment decisions in UK primary 
care.18 We recruited adults (aged ≥18) presenting in pri-
mary care with new or existing symptoms of depression 
(ascertained by PHQ-9), who were not in receipt of cCBT 
or specialist psychological therapy at the time of 
recruitment. Potential participants were recruited 
either directly by their GP or by letter of invitation if 
their clinical records noted that they had depression. 
We checked participants’ access to the internet at base-
line (before randomisation). Participants either had 
access to the internet at home or through a close friend 
or relative. Some participants were happy to access the 
internet in a central location including a local library, 
local MIND (a UK based mental health charity), and GP 
practice (although few participants accessed the inter-
net at these locations).
We excluded patients who were known by their GP to 
be actively suicidal; experiencing psychotic symptoms; 
depressed in the postnatal period; or had recently been 
bereaved. Patients with previous treatment experience 
of CBT were not excluded.
All participants completed a baseline assessment 
before randomisation with several self report question-
naires. Participants also completed a diagnostic self 
reported computer based interview (the clinical inter-
view schedule-revised, CIS-R),19  which assesses sever-
ity and diagnosis of depression, along with other 
common mental health disorders, according to ICD-10 
(international classification of diseases, 10th revision) 
criteria.20
Participants gave written informed consent before 
taking part in the study. Recruitment for the trial took 
place between August 2009 and March 2011 in general 
practices in York, Manchester, Sheffield, Bristol, Hull, 
and the northeast of England. Patient safety was moni-
tored by systematic monitoring of adverse events and 
serious adverse events; each was reviewed by a clinical 
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member of the team for relatedness to trial interven-
tions (in line with an extension to the CONSORT state-
ment21). Appendix 2 contains the information sheet 
given to participants.
randomisation, concealment, and blinding
Participants were allocated by simple randomisation to 
one of three groups without any restrictions placed on 
the sequence (that is, no blocking or stratification was 
included in the randomisation procedure). At the point 
of recruitment we used an automated computer data 
entry system to conceal treatment allocation from the 
study researchers. This was administered remotely by 
the York Trials Unit and used a computer generated 
code. Because of the nature of the intervention, none of 
the participants, general practices, or clinicians could 
be blinded to treatment allocation. GPs were informed 
by letter of the participant’s treatment allocation.
Follow-up
We collected follow-up data between December 2009 
and April 2013. Participants were asked to provide data 
at four, 12, and 24 months after randomisation with a 
series of self completed questionnaires. The primary 
outcome endpoint was the four month follow-up as this 
represented the period at which we expected to observe 
the largest effect between groups.12 Data were collected 
at 12 and 24 months to investigate any longer term out-
comes that could be attributed to the intervention.
To maximise retention, researchers arranged tele-
phone or face to face interviews to facilitate data collec-
tion at four, 12, and 24 month follow-up points. 
Participants were sent the questionnaire by post if tele-
phone or face to face contact was not possible. Research-
ers performing the outcome assessments were not blind 
to treatment allocation, though observer bias was mini-
mised by the use of self report questionnaires. A mone-
tary voucher was offered to study participants in 
recognition of time spent in completing follow-up and 
was non-contingent on response in line with evidence 
to enhance retention.22
intervention and comparator (usual gp care)
This was a pragmatic trial. We imposed no constraints 
on usual GP care in the control or intervention groups, 
and participants were therefore free during the trial to 
access any treatment usually available in primary care, 
including the use of antidepressants, counselling, psy-
chological services (including Improving Access to Psy-
chological Therapy services, which were present in 
most sites during the course of the trial), or secondary 
care mental health services.
Supported cCBT intervention groups
Participants in the intervention groups were each 
offered supported cCBT in addition to usual GP care. 
Participants were encouraged to access their allocated 
cCBT packages in their own home or at that of a friend/
relative with a broadband internet connection. To 
ensure those without computer access were not denied 
participation in the REEACT trial, we also gave 
 information on the location of free to use internet con-
nected computers (though few participants used this 
mode of access).
The cCBT packages were supported by weekly tele-
phone calls to exceed or replicate (by telephone) a level 
of support offered in earlier developer led trials16 15  and 
in view of the evidence that professionally supported 
treatment was more likely to be effective than unsup-
ported computer self help programmes.12 We also 
offered a level of support that replicated or exceeded 
the support offered in routine NHS psychological ther-
apy services in primary care to ensure the results of the 
REEACT study were generalisable to UK NHS services. 
Trained technicians delivered the telephone support. 
Participants in the two intervention groups were 
encouraged by phone to engage with the course of com-
puterised therapy, and technical issues relating to com-
puters and the online programmes were also resolved. 
With the participants’ consent we recorded these phone 
calls to supervise the telephone support staff and to 
ensure fidelity to this model of technical/motivational 
support. As part of quality assurance, an experienced 
trial clinician scrutinised tapes to ensure delivery of 
technical support in line with the treatment protocol.
Experimental group 1
Beating the Blues (Ultrasis, www.ulltrasis.com) is an 
interactive, multimedia, cCBT package comprising a 15 
minute introductory video followed by eight therapy 
sessions lasting about 50 minutes. The programme is 
entirely online, and there is no interaction with clini-
cians or individualised feedback on computer sessions. 
There are homework exercises between the sessions. 
Developer led trials have shown that Beating the Blues 
is efficacious in reducing symptoms of depression.15
Experimental group 2
MoodGYM (ANU, http://moodgym.anu.edu.au) is a free 
to use web based CBT programme for depression devel-
oped and copyrighted at the Australian National Uni-
versity Centre for Mental Health Research. It consists of 
five interactive modules, which are made available 
sequentially on a weekly basis, with revision of all 
aspects of the programme in the sixth week. The pro-
gramme is entirely online, and there is no interaction 
with clinicians or individualised feedback on computer 
sessions. Developer led trials have shown that 
MoodGYM is efficacious in reducing symptoms of 
depression.16
We were able to check uptake and online use of each 
computer programme with reference to computer use 
records and by self report. We also recorded the number 
and duration of telephone support calls that were 
offered and used.
outcomes
The primary outcome was the PHQ-9 at the four month 
follow-up. The PHQ-9 is a self report measure that 
includes the cardinal cognitive and somatic symptoms 
of depression as defined by the American Psychiatric 
Association Diagnostic and Statistical Manual, version 
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four (DSM-IV).23  Scores can range from zero to 27, with a 
recommended cut point of ≥10, which indicates the 
need for treatment and has been validated against stan-
dardised diagnoses of clinical depression.17 Severity of 
depression was reported as continuous PHQ-9 scores 
and as a dichotomous outcome according to the propor-
tion of participants who were improved with PHQ-9 
scores <10. The dichotomised score was set as the pri-
mary outcome, and sample size was ascertained on the 
basis of the ability of the trial to detect differences in the 
proportion of participants who were improved.
Secondary outcomes included the SF-36 as a measure 
of health related quality of life. The SF-36 scoring algo-
rithm produces a physical component score (PCS) and 
mental component score (MCS).24 25  We also recorded 
health state utility with the EQ-5D26  and general psy-
chological wellbeing with the clinical outcomes in rou-
tine evaluation-outcome measure (CORE-OM). This 
instrument measures a range of domains including 
wellbeing, psychological symptoms, function, and 
risk.27
patient involvement
Patient and members of the public were involved at sev-
eral stages of the trial, including the design, manage-
ment, and conduct of the trial. We received input from 
patients who had lived with depression and common 
mental health problems in the design of the trial mate-
rials and management oversight through membership 
of the trial steering committee. A user led organisation 
(Anxiety UK and Self-Help Services) acted as co-appli-
cant (through its chief executive) and collaborator. We 
carefully assessed the burden of the trial interventions 
on patients. We intend to disseminate the main results 
to trial participants and will seek patient and public 
involvement in the development of an appropriate 
method of dissemination.
Sample size
We designed our trial to test whether computerised CBT 
represents a clinically effective addition to usual GP care 
and whether the free to use computerised package did 
not represent a less effective (non-inferior) choice of 
therapy for patients. It was powered to capture any ben-
efit of computerised CBT over usual GP care alone and to 
test the non-inferiority of free to use cCBT. We based our 
sample size calculation on the usual care arm of primary 
care depression trials, where the proportion of patients 
responding to usual care was in the region of 0.6.28  This 
proportion is similar to that found in a UK Health Tech-
nology Assessment trial of antidepressants in primary 
care.29 We regarded a figure of not more than 0.15 below 
this proportion as being acceptable, given the additional 
care options that are available to patients who do not 
initially respond to cCBT within a stepped care frame-
work. In our original calculation, to detect non-inferior-
ity with the percentage success in both groups as 60% 
and a non-inferiority margin of 15% with over 80% 
power and assuming 25% attrition, we required 200 par-
ticipants in each of the three arms. Recruitment to the 
trial went better than expected, and the trial could have 
finished recruitment early, but there were slightly higher 
levels of attrition so we re-estimated sample sizes. To 
retain similar levels of power to detect non-inferiority 
between the free to use and commercial cCBT pro-
grammes, while allowing for 35% attrition, we sought 
690 participants (230 participants in each of the three 
arms). The trial was also powered to detect a difference 
of 15% between the usual GP care arm and either of the 
two cCBT arms with a conventional power analysis. The 
assumption of 80% power (5% two sided significance) to 
show a difference in the proportion participants 
improved (PHQ-9<10) of 0.6 versus 0.75 (equivalent to an 
odds ratio of 2 for not depressed or an odds ratio of 0.5 
for depressed) at four months required a sample size of 
149 in each group or 230 after allowance for 35% attri-
tion (that is, 690 in total).
Statistical analysis
We compared outcome measures separately between 
the following groups of participants: Beating the Blues 
versus usual GP care (superiority); MoodGYM versus 
usual GP care (superiority); and MoodGYM versus Beat-
ing the Blues (non-inferiority).
For each group comparison, we applied similar anal-
yses depending on type of comparison (superiority or 
non-inferiority) and the inclusion of potentially 
important covariates. All analyses were performed in 
Stata 13, following a pre-specified analysis plan 
approved by the trial steering committee. All analyses 
were conducted on an intention to treat basis, with all 
participants included in the groups to which they were 
randomised, with two sided significance tests at the 5% 
significance level for superiority comparisons. All 
baseline data were summarised by treatment group 
and reported descriptively, with no formal statistical 
comparisons.
Primary analysis
Groups were compared with a logistic regression model 
of dichotomised PHQ-9 scores with adjustments for sex, 
age, severity of depression at baseline, duration of 
depression, and level of anxiety. We obtained odds 
ratios and corresponding 95% confidence intervals 
from this model. For the comparison between Beating 
the Blues and MoodGYM, we constructed 90% two 
sided confidence intervals to maintain 5% significance 
levels throughout. With this method, the free to use 
cCBT programme MoodGYM would not be inferior to the 
commercial pay to use cCBT programme Beating the 
Blues at the 5% level if the upper boundary was below 
the prespecified margin of non-inferiority (15% differ-
ence in proportions, which corresponded with 1.44 for 
the odds ratio).
Secondary analyses
We repeated the primary analysis for the 12 and 24 
month dichotomised PHQ-9 data using the same meth-
ods as outlined above. We also analysed all time points 
in one model rather than individual analyses at each 
time point using a repeated measures multilevel logistic 
regression model. The values at four, 12, and 24 months 
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were the outcome measures, and the baseline PHQ-9 
score, age, sex, duration of depression, level of anxiety, 
treatment group, and time were included as fixed 
effects; an interaction between treatment and time was 
also included in the model. Participants were treated as 
random effects (to allow for clustering of data within 
each participant). Different covariance patterns were 
assessed for the repeated measurements within partici-
pants: unstructured, independent, exchangeable, and 
identity. We estimated overall odds ratios and corre-
sponding 95% (or 90% for non-inferiority) confidence 
intervals as well as individual odds ratios at each time 
point (four, 12, and 24 months) from these models. The 
PHQ-9 in its continuous form, CORE-OM, and SF-36 
component scores were analysed with a multilevel lin-
ear mixed model following a similar procedure to those 
outlined above for the dichotomised PHQ-9 scores. The 
model made adjustments for the same covariates. For 
continuous outcomes we also reported standard effect 
sizes (Hedges G).
The statistical analysis and reporting of the REEACT 
trial followed the CONSORT guidelines.30
Results
One hundred GP practices agreed to take part in the 
study, with participants being recruited from 83 of 
these practices. Potential participants were either 
referred or responded to a letter inviting them to par-
ticipate in the trial between August 2009 and March 
2011. Of 1273 people assessed, 691 eligible and con-
senting participants were successfully randomised 
(fig 1). At baseline, 242 people were allocated to the 
MoodGYM intervention arm, 210 to the Beating the 
Blues intervention arm, and 239 to the usual GP care 
arm (unequal numbers were expected by chance 
under conditions of simple randomisation). Follow-up 
was achieved for 526 (76%) participants at the four 
month primary outcome, 484 (70%) at 12 months, and 
461 (67%) at 24 months.
The randomised groups were well balanced and 
similar on entry to the trial in terms of age, sex, sever-
ity of depression, duration of depression, use of anti-
depressant drugs, and educational attainment 
(table 1 ). The median severity of depression across all 
groups was 17, which broadly equated with a moder-
ate severity of depression.31 Over a third of partici-
pants had had depression for more than a year. When 
we applied diagnosis according to the CISR, 81% of 
participants had a confirmed depressive episode 
according to ICD criteria, with no difference between 
groups (82.2% of participants in the Beating the Blues 
group, 81.1% of participants in the usual GP care 
group, and 79.9% of participants in the MoodGYM 
group).
primary analysis
At four months, 83 of 165 (50%) participants in the 
Beating the Blues group, 78 of 179 (44%) participants 
in the usual GP care group, and 89 of 182 (49%) par-
ticipants in the MoodGYM group remained depressed 
by the criterion of score ≥10 on the PHQ-9 (table 2 ). 
Results from the logistic regression (table 3 ) showed 
that there was no statistical evidence of a difference 
between Beating the Blues and usual GP care at four 
Assessed for eligibility (n=1273)
Randomised (n=691)
Allocated to Beating the Blues and usual
  GP care (n=210)
Received Beating the Blues (n=210)
Primary outcome analysis (n=165)
Analysis at 12 months (n=153)
Analysis at 24 months (n=143)
Primary outcome analysis (n=179)
Analysis at 12 months (n=166)
Analysis at 24 months (n=158)
Primary outcome analysis (n=182)
Analysis at 12 months (n=165)
Analysis at 24 months (n=160)
4 month follow-up (n=165; 79%)
Lost to follow-up (n=33)
Withdrawn from intervention (n=15)
Full withdrawal (n=12)
12 month follow-up (n=153; 73%)
Lost to follow-up (n=35)
Full withdrawal (n=10)
24 month follow-up (n=143; 68%)
Lost to follow-up (n=39)
Full withdrawal (n=4)
Incomplete primary outcome (n=2)
4 month follow-up: (n=179; 75%)
Lost to follow-up (n=47)
Full withdrawal (n=13)
12 month follow-up (n=166; 69%)
Lost to follow-up (n=48)
Full withdrawal (n=12)
24 month follow-up (n=158; 66%)
Lost to follow-up (n=54)
Full withdrawal (n=2)
4 month follow-up (n=182; 75%)
Lost to follow-up (n=48)
Withdrawn from intervention (n=9)
Full withdrawal (n=12)
12 month follow-up (n=165; 68%)
Lost to follow-up (n=56)
Full withdrawal (n=9)
24 month follow-up (n=160; 66%)
Lost to follow-up (n=59)
Full withdrawal (n=2)
Allocated to usual GP care (n=239) Allocated to MoodGYM and usual GP care
  (n=242)
Received MoodGYM (n=242)
Excluded (n=582):
Did not meet inclusion criteria (n=234)
Declined to participate (n=348)
Fig 1 | Selection, randomisation, and flow of participants through trial of computerised cognitive behaviour therapy for 
depression in primary care
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months (odds ratio 1.19, 95% confidence interval 
0.75 to 1.88) or between MoodGYM and usual GP care 
at four months (0.98, 0.62 to 1.56; table 3 ). For the 
non-inferiority comparison between MoodGYM and 
Beating the Blues, the odds ratio at four months was 
0.91 (0.62 to 1.34; P=0.69). The upper 90% confidence 
limit for the odds ratio was 1.34, thus satisfying sta-
tistical criteria for non-inferiority of MoodGYM 
table 2 | phq-9 summary (phq-9 ≥10) by duration of 
follow-up and treatment group. Figures are numbers 
(percentage) of participants
Beating the Blues usual gp care MoodgyM
Baseline 210 (100) 239 (100) 242 (100)
4 months ≥10 83/165 (50) 78/179 (44) 89/182 (49)
12 months 54/153 (35) 66/166 (40) 50/165 (30)
24 months 60/143 (42) 61/158 (39) 55/160 (34)
table 1 | Baseline characteristics of participants in study of computerised cognitive behaviour therapy for depression in 
primary care. Figures are numbers (percentages) of participants unless stated otherwise
Characteristic at baseline
Beating the 
Blues (n=210)
usual gp care 
(n=239)
MoodgyM 
(n=242) total (n=691)
Mean (SD) age (years) 39.61 (12.34) 40.52 (12.64) 39.43 (12.96) 39.86 (12.65)
Age >65 6 (3) 11 (5) 12 (5) 29 (4)
Women 142 (68) 163 (68) 157 (65) 462 (67)
Depression severity (PHQ-9):
 Mean (SD) 16.78 (4.21) 16.32 (4.52) 16.87 (3.99) 16.65 (4.25)
 Median (range) 17 (10-27) 16 (10-27) 17 (10-26) 16. 17 (10-27)
Previous episodes of depression:
 Yes 144 (69) 178 (75) 169 (70) 491 (71)
 No 65 (31) 60 (25) 72 (30) 197 (29)
 Don’t know 1 (0) 0 (0) 1 (1) 2 (0)
 No response 0 (0) 1 (0) 0 (0) 1 (0)
No of episodes of depression:
 No of participants in group 144 178 169 491
 1 42 (29) 49 (28) 44 (26) 135 (27)
 2 34 (24) 49 (28) 31 (18) 114 (23)
 3 12 (8) 21 (12) 23 (14) 56 (11)
 4 10 (7) 7 (4) 14 (8) 31 (6)
 ≥5 22 (15) 24 (13) 22 (13) 68 (14)
 Chronically depressed 19 (13) 21 (12) 30 (18) 70 (14)
 Don’t know 4 (3) 7 (4) 5 (3) 16 (3)
 No response 1 (1) 0 (0) 0 (0) 1 (0)
Previously prescribed antidepressants:
 No of participants in group 144 178 169 491
 Yes 129 (90) 152 (85) 149 (88) 430 (88)
 No 14 (10) 26 (15) 20 (12) 60 (12)
 Don’t know 1 (1) 0 (0) 0 (0) 1 (0)
Seen anyone other than GP for depression:
 No in group 104 129 132 365
 Psychiatrist 25 (24) 37 (28) 31 (23) 93 (25)
 Psychologist 21 (20) 21 (16) 35 (26) 77 (21)
 Counsellor 79 (76) 100 (76) 95 (70) 273 (75)
 Community psychiatric nurse 15 (14) 26 (20) 19 (14) 60 (16)
 Social worker 2 (2) 3 (2) 1 (1) 6 (2)
 CAB 2 (2) 1 (1) 2 (1) 5 (1)
 Other statutory/voluntary agency 11 (11) 18 (14) 9 (7) 9 (7)
 Don’t know 1 (1) 1 (1) 2 (1) 3 (1)
Duration of depression:
 0 (no problem recorded) 9 (4) 13 (5) 14 (6) 36 (5)
 1 (present for <2 weeks) 3 (1) 0 (0) 2 (1) 5 (1)
 2 (present for 2 weeks-6 months) 67 (32) 96 (40) 79 (33) 242 (35)
 3 (present for 6 months-1 year) 49 (24) 46 (19) 43 (18) 138 (20)
 4 (present for 1-2 years) 24 (12) 30 (13) 37 (15) 91 (13)
 5 (present >2 years) 56 (27) 53 (22) 64 (27) 173 (25)
Duration of anxiety:
 0 (no problem recorded) 31 (15) 33 (14) 33 (14) 97 (14)
 1 (present for <2 weeks) 6 (3) 5 (2) 6 (3) 17 (2)
 2 (present for 2 weeks-6 months) 57 (27) 79 (33) 63 (26) 199 (29)
 3 (present for 6 months-1 year) 32 (15) 41 (17) 34 (14) 107 (16)
 4 (present for 1-2 years) 24 (12) 21 (9) 32 (13) 77 (11)
 5 (present >2 years) 58 (28) 59 (25) 71 (30) 188 (27)
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 compared with Beating the Blues. Results of the sen-
sitivity analyses were consistent when we adjusted 
for centre and when we assessed the impact of drop 
outs under best (missing=not depressed) and worst 
case (missing=depressed) scenarios (table 3).
Secondary analyses
Results from the PHQ-9 logistic regression highlighted 
that there was no statistical evidence of a difference 
between Beating the Blues and usual GP care across 
any of the time points (odds ratios 0.77 (95%  confidence 
interval 0.47 to 1.26) at 12 months and 1.00 (0.60 to 1.68) 
at 24 months; table 3  and fig 2 ). There was some statis-
tical evidence of a difference in favour of MoodGYM 
versus usual GP care at 12 months (0.56, 0.34 to 0.93), 
but this was no longer evident at 24 months (0.68, 0.41 
to 1.15; table 3  and fig 2). For the non-inferiority com-
parison, the upper 90% confidence limit for the odds 
ratio at 12 and 24 months was below the prespecified 
margin, thus satisfying statistical criteria for non-infe-
riority (0.77 (0.50 to 1.18) at 12 months and 0.72 (0.47 to 
1.11) at 24 months). The results from the multilevel 
logistic regression model were similar to those from the 
logistic regression models at each individual time 
point. There was no evidence of an overall difference 
between either programme compared with usual 
GP care (0.99 (0.57 to 1.70) for Beating the Blues v usual 
GP care; and 0.68 (0.42 to 1.10) for MoodGYM v usual GP 
care). The results for the non-inferiority comparison 
between MoodGYM and Beating the Blues at four 
months, however, did change: the upper 90% confi-
dence limit for the odds ratio was above the prespeci-
fied margin, thus no longer satisfying statistical criteria 
for non-inferiority with Beating the Blues inferior to 
MoodGYM (0.94, 0.57 to 1.55).
There was no statistical evidence of a difference on 
the overall (including all time points) mean depression 
scores, physical and mental component scores on the 
quality of life scale (SF-36), and CORE-OM scores for 
Beating the Blues compared with usual GP care alone 
(table 4-7). The standard effect size (Hedges G) for 
depression scores across all time points for Beating the 
Blues versus usual GP care alone showed no evidence 
of a difference (−0.02, 95% confidence interval −0.22 to 
0.19; table 4 ). There was no evidence of a difference on 
the overall (including all time points) mean depression 
scores (table 4 ) and physical component scores on the 
SF-36 (table 5 ) for MoodGYM compared with usual GP 
care alone. The standard effect size (Hedges G) across 
all time points for MoodGYM versus usual GP care alone 
was small and not significant (0.09, −0.11 to 0.28; 
table 4 ). There was, however, evidence of a difference in 
table 3 | results from logistic regression and mixed models. odds ratios are odds of being depressed
Comparison
odds ratio (95% Ci); p value
Beating the Blues v usual 
gp care
MoodgyM v usual gp 
care
MoodgyM v Beating the 
Blues
logistic regression result*
4 months 1.19 (0.75 to 1.88); 0.46 0.98 (0.62 to 1.56); 0.95 0.91 (0.62† to 1.34†); 0.69
12 months 0.77 (0.47 to 1.26); 0.29 0.56 (0.34 to 0.93); 0.02 0.77 (0.50† to 1.18†); 0.31
24 months 1.00 (0.60 to 1.68); 0.99 0.68 (0.41 to 1.15); 0.15 0.72 (0.47† to 1.11†); 0.21
Sensitivity analyses at 4 months
Adjusted for centre 1.19 (0.83 to 1.71); 0.35 0.98 (0.67 to 1.45); 0.94 0.91 (0.64† to 1.30†); 0.67
Best case scenario (missing=not depressed) 1.34 (0.90 to 2.01); 0.15 1.12 (0.75 to 1.68); 0.58 0.90 (0.65† to 1.27†); 0.62
Worst case scenario (missing=depressed) 1.05 (0.70 to 1.57); 0.83 1.00 (0.68 to 1.49); 0.99 1.03 (0.73† to 1.44†); 0.89
Mixed model‡
4 months 1.27 (0.70 to 2.28); 0.43 1.13 (0.61 to 2.10); 0.70 0.94 (0.57† to 1.55†); 0.84
12 months 0.66 (0.32 to 1.34); 0.24 0.44 (0.22 to 0.88); 0.02 0.73 (0.40† to 1.32†); 0.39
24 months 1.16 (0.44 to 3.05); 0.77 0.62 (0.30 to 1.29); 0.20 0.60 (0.29† to 1.26†); 0.26
*Adjusted for sex, age, baseline depression severity, depression duration and level of anxiety.
†90% confidence interval for non-inferiority comparison.
‡Adjusted for sex, age, baseline depression severity, depression duration, level of anxiety, month, treatment and an interaction between month and 
treatment as fixed effects. 
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Fig 2 | depression status measured with phq-9 across all 
follow-up points. Means are all predicted means and 95% 
confidence intervals estimated from mixed model with sex, 
age, baseline phq-9 score, duration of depression, level of 
anxiety, month, treatment, and interaction between month 
and treatment as fixed effects
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favour of MoodGYM for depression scores at 12 months 
(table 4 ). There was also evidence of a difference in 
favour of MoodGYM on the overall (including all time 
points) mean CORE-OM (table 7 ) scores and mental 
component scores on the SF-36 (table 5) compared with 
usual GP care alone; with evidence of a difference in 
CORE-OM scores at 12 months and mental component 
scores on the SF-36 at 12 and 24 months.
participant safety
In total, 302 participants reported 745 non-serious 
adverse events: 93 participants (264 events) in the 
 Beating the Blues group, 110 participants (241 events) 
in the usual GP care group, and 99 participants (240 
events) in the MoodGYM group. Table 8 summarises 
adverse events by trial arm. Across all participants, 
49 serious adverse events were recorded from 
table 6 | linear mixed model for secondary analyses, physical component score (pCS)
Mean (95% Ci)* difference (95% Ci),  
p value effect size (95% Ci)intervention usual gp care
overall
Beating the Blues v usual GP care 48.66 (47.05 to 50.28) 49.55 (47.86 to 51.23) −0.89 (−2.29 to 0.52), 0.22 −0.08 (−0.29 to 0.13)
MoodGYM v usual GP care 48.87 (47.11 to 50.63) 49.91 (48.05 to 51.76) −1.04 (−2.41 to 0.33), 0.14 −0.08 (−0.28 to 0.12)
4 months
Beating the Blues v usual GP care 49.18 (47.44 to 50.92) 49.85 (48.05 to 51.64) −0.67 (−2.33 to 0.99), 0.43 −0.06 (−0.26 to 0.15)
MoodGYM v usual GP care 49.86 (47.97 to 51.75) 50.21 (48.23 to 52.19) −0.35 (−2.04 to 1.33), 0.68 −0.03 (−0.23 to 0.18)
12 months
Beating the Blues v usual GP care 48.61 (46.80 to 50.43) 49.73 (47.86 to 51.61) −1.12 (−2.95 to 0.71), 0.23 −0.09 (−0.30 to 0.12)
MoodGYM v usual GP care 48.85 (46.96 to 50.73) 50.06 (48.07 to 52.05) −1.21 (−2.91 to 0.49), 0.16 −0.09 (−0.29 to 0.11)
24 months
Beating the Blues v usual GP care 48.19 (46.17 to 50.22) 49.06 (47.02 to 51.10) −0.87 (−3.06 to 1.32), 0.44 −0.06 (−0.27 to 0.15)
MoodGYM v usual GP care 47.89 (45.82 to 49.97) 49.45 (47.30 to 51.60) −1.56 (−3.61 to 0.50), 0.14 −0.11 (−0.31 to 0.10)
*Predicted means (95% CI) from mixed model with sex, age, baseline PCS, depression duration, level of anxiety, month, treatment, and interaction 
between month and treatment as fixed effects.
table 4 | linear mixed model for secondary analyses, phq-9 continuous
Mean (95% Ci)*
difference (95% Ci), p value effect size (95% Ci)intervention usual gp care 
overall
Beating the Blues v usual GP care 8.06 (6.92 to 9.20) 7.93 (6.74 to 9.13) 0.12 (−0.87 to 1.11), 0.81 −0.02 (−0.22 to 0.19)
MoodGYM v usual GP care 8.49 (7.26 to 9.72) 9.30 (8.00 to 10.60) −0.81 (−1.75 to 0.13), 0.09 0.09 (−0.11 to 0.28)
4 months
Beating the Blues v usual GP care 9.18 (7.94 to 10.42) 8.46 (7.18 to 9.73) 0.72 (−0.46 to 1.90), 0.23 −0.08 (−0.28 to 0.12)
MoodGYM v usual GP care 9.86 (8.55 to 11.18) 9.80 (8.42 to 11.18) 0.06 (−1.09 to 1.22), 0.91 −0.01 (−0.20 to 0.19)
12 months
Beating the Blues v usual GP care 7.20 (5.94 to 8.46) 7.83 (6.53 to 9.13) −0.63 (−1.87 to 0.62), 0.33 0.07 (−0.13 to 0.27)
MoodGYM v usual GP care 7.63 (6.31 to 8.95) 9.22 (7.83 to 10.60) −1.59 (−2.75 to -0.42), 0.008 0.16 (−0.03 to 0.36)
24 months
Beating the Blues v usual GP care 7.79 (6.47 to 9.12) 7.52 (6.16 to 8.88) 0.28 (−1.10 to 1.65), 0.69 −0.03 (−0.23 to 0.17)
MoodGYM v usual GP care 7.97 (6.61 to 9.33) 8.88 (7.45 to 10.30) −0.91 (−2.16 to 0.35), 0.16 0.09 (−0.11 to 0.29)
*Predicted means (95% CI) from mixed model with sex, age, baseline depression severity, depression duration, level of anxiety, month, treatment, and 
interaction between month and treatment as fixed effects.
table 5 | linear mixed model for secondary analyses, mental component score (MCS)
Mean (95% Ci)* difference (95% Ci), p 
value effect size (95% Ci)intervention usual gp care
overall
Beating the Blues v usual GP care 38.52 (35.77 to 41.27) 37.50 (34.62 to 40.38) 1.02 (−1.34 to 3.37), 0.40 0.05 (−0.16 to 0.26)
MoodGYM v usual GP care 38.98 (36.03 to 41.92) 35.99 (32.88 to 39.11) 2.98 (0.73 to 5.24), 0.009 0.14 (−0.06 to 0.34)
4 months
Beating the Blues v usual GP care 35.23 (32.28 to 38.17) 36.33 (33.29 to 39.37) −1.10 (−3.85 to 1.64), 0.43 −0.05 (−0.26 to 0.15)
MoodGYM v usual GP care 35.07 (31.90 to 38.23) 34.87 (31.54 to 38.20) 0.20 (−2.60 to 2.99), 0.89 0.01 (−0.19 to 0.21)
12 months
Beating the Blues v usual GP care 41.58 (38.55 to 44.60) 38.25 (35.11 to 41.39) 3.32 (0.37 to 6.28), 0.03 0.16 (−0.05 to 0.37)
MoodGYM v usual GP care 40.91 (37.77 to 44.05) 36.66 (33.33 to 40.00) 4.25 (1.47 to 7.02), 0.003 0.19 (−0.02 to 0.39)
24 months
Beating the Blues v usual GP care 38.76 (35.52 to 41.99) 37.92 (34.62 to 41.22) 0.84 (−2.49 to 4.17), 0.62 0.04 (−0.17 to 0.25)
MoodGYM v usual GP care 40.95 (37.68 to 44.23) 36.44 (33.03 to 39.86) 4.51 (1.51 to 7.51), 0.003 0.19 (−0.01 to 0.39)
*Predicted means (95% CI) from mixed model with sex, age, baseline MCS, depression duration, level of anxiety, month, treatment, and interaction 
between month and treatment as fixed effects.
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39  participants. Of these, 39 were judged to be unre-
lated and nine unlikely to be related to the trial inter-
vention. We were unable to make a judgment of 
relatedness to the trial intervention for one serious 
adverse event reported because of limited information 
provided. Five of the serious adverse events were 
referred to the data monitoring and ethics committee 
for discussion, and two were referred to the research 
ethics committee. Of the 49 serious adverse events, 
40 (82%) involved inpatient admission to hospital, 
table 8 | Summary of adverse events (non-serious (nSae) and serious (Sae)). Figures are numbers (percentage) of participants
Beating the 
Blues (n=210)
usual gp 
care (n=239)
MoodgyM 
(n=242)
total 
(n=691)
non-serious adverse events
Total 264 241 240 745
No of participants with ≥1 event 93 (44) 110 (46) 99 (41) 302 (44)
No per patient:
 1 27 (29) 49 (45) 36 (36) 112 (37)
 2 30 (32) 31 (28) 21 (21) 82 (27)
 3 14 (15) 13 (12) 22 (22) 49 (16)
 4 6 (7) 7 (6) 12 (12) 25 (8)
 5 5 (5) 6 (6) 6 (6) 17 (6)
 ≥6 11 (12) 4 (4) 2 (2) 17 (6)
Serious adverse events
Total 19 19 11 49
No of participants with ≥1 event 15 (7) 15 (6) 9 (4) 39 (6)
Events per patient:
 1 12 (80) 11 (73) 7 (78) 30 (77)
 2 2 (13) 4 (27) 2 (22) 8 (21)
 3 1 (7) 0 0 1 (3)
Relation to treatment:
 Unrelated 18 (95) 15 (79) 6 (55) 39 (80)
 Unlikely to be related 0 4 (21) 5 (46) 9 (18)
 Possibly related 0 0 0 0
 Probably related 0 0 0 0
 Definitely related 0 0 0 0
 Unable to assess* 1 (5) 0 0 1 (2.0)
Referred to DMEC 0 3 (16) 2 (18) 5 (10)
Referred to REC 0 2 (11) 0 2 (4)
Event details:
 Involved inpatient admission† 17 (90) 13 (68) 10 (91) 40 (82)
 Life threatening†‡ 0 6   (32) 1 (9) 7 (14)
 Patient died 2 (11) 0 0 2 (4)
 Involved persistent or considerable disability or incapacity‡ 0 0 0 0
 Resulted in congenital anomaly or birth defect 0 0 0 0
DMEC=data monitoring ethics committee, REC=research ethics committee.
*Researcher was informed that participant had recently been admitted to hospital but when contacted participant did not provide further information 
and withdrew from study.
†One SAE was classed as both involving inpatient admission and life threatening.
‡One SAE was classed as both life threatening and involving persistent or considerable disability or incapacity.
table 7 | linear mixed model for secondary analyses, Core-oM
Mean (95% Ci)
difference (95% Ci), p value effect size (95% Ci)intervention usual gp care
overall
Beating the Blues v usual GP care 11.74 (10.27 to 13.21) 12.18 (10.64 to 13.71) −0.44 (−1.70 to 0.82), 0.50 0.04 (−0.17 to 0.25)
MoodGYM v usual GP care 11.98 (10.47 to 13.50) 13.14 (11.55 to 14.73) −1.16 (−2.31 to 0.002), 0.05 0.11 (−0.10 to 0.31)
4 months
Beating the Blues v usual GP care 12.87 (11.31 to 14.43) 12.75 (11.14 to 14.36) 0.12 (−1.33 to 1.57), 0.87 −0.01 (−0.22 to 0.20)
MoodGYM v usual GP care 13.61 (12.01 to 15.20) 13.69 (12.02 to 15.36) −0.09 (−1.44 to 1.27), 0.90 0.01 (−0.19 to 0.21)
12 months
Beating the Blues v usual GP care 10.51 (8.91 to 12.11) 12.00 (10.34 to 13.66) −1.49 (−3.04 to 0.06), 0.06 0.13 (−0.07 to 0.34)
MoodGYM v usual GP care 10.87 (9.25 to 12.48) 12.98 (11.28 to 14.68) −2.12 (−3.54 to −0.69), 0.004 0.18 (−0.02 to 0.38)
24 months
Beating the Blues v usual GP care 11.84 (10.13 to 13.55) 11.78 (10.05 to 13.51) 0.06 (−1.68 to 1.80), 0.95 −0.01 (−0.21 to 0.20)
MoodGYM v usual GP care 11.48 (9.80 to 13.16) 12.74 (11.00 to 14.49) −1.27 (−2.80 to 0.27), 0.11 0.11 (−0.10 to 0.31)
*Predicted means (95% CI) from mixed model with sex, age, baseline CORE-OM, depression duration, level of anxiety, month, treatment, and interaction 
between month and treatment as fixed effects.
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seven were life threatening, and two resulted in par-
ticipants dying.
uptake and use of computerised CBt and telephone 
support
After allocation, 83% (n=175) of Beating the Blues par-
ticipants and 77% (n=186) of MoodGYM participants 
accessed the programmes (as ascertained by computer 
login records). When asked at four months after rando-
misation, 19% of the usual GP care group reported hav-
ing used computerised CBT; either on the 
recommendation of their GP, by self referral, or at the 
recommendation of a mental health professional.
From computer verified records, we ascertained that 
the median number of sessions completed for Beating 
the Blues was two (interquartile range 0-5), and the 
most commonly used (median) number of sessions was 
one (out of eight computer sessions). For MoodGYM the 
median number of sessions completed was one (0-2), 
and the most commonly used number of sessions was 
one (out of six computer sessions). Of those partici-
pants who started the programmes, 31 participants 
(18%) completed all eight sessions of Beating the Blues, 
and 29 participants (16%) completed all six sessions of 
MoodGYM.
We attempted a median of 13 contacts to participants 
allocated to Beating the Blues (interquartile range 11-16) 
and MoodGYM (10-16). A total mean of 6.0 (3-8) techni-
cal telephone support calls were made to Beating the 
Blues participants and 6.8 (4-9) to MoodGYM partici-
pants. Of the technical telephone support calls made, 
the mean number of calls answered by participants was 
3.1 (1-5) for Beating the Blues participants and 3.3 (1-5) 
for MoodGYM participants. The total mean number of 
minutes of technical support calls delivered to partici-
pants was 6.2 (2-8) minutes for Beating the Blues 
 participants and 6.5 minutes (2-9) for MoodGYM partic-
ipants. The mean number of emails sent was 5.3 (2-8) for 
Beating the Blues participants and 5.0 (1-8) for 
MoodGYM participants. Texts were rarely sent (mean of 
<0.1 texts sent to both Beating the Blues and MoodGYM 
participants).
usual care received
Examination of GP medical records showed that partic-
ipants received a range of treatments as part of the 
usual care from their GP (table 9 ). Participants received 
a range of antidepressant drugs and access to various 
mental health services, including referral to Improving 
Access to Psychological Therapy services, community 
mental health teams, psychiatrists, psychologists, and 
counsellors. Such services were used by similar propor-
tions of participants across each of the three groups. In 
addition, participants visited their GP to a comparable 
extent across the three groups. We present the results of 
a full economic evaluation elsewhere.32
discussion
principal findings
The REEACT trial showed that for the primary outcome 
of severity of depression at four months there was no 
significant benefit for supported cCBT in addition to 
usual GP care. Confidence intervals were wide for these 
estimates, and there was 24% drop out at four months. 
The estimates and 95% confidence intervals at our pri-
mary time point of interest were all larger than our orig-
inal sample size estimate (odds ratio 0.5). This negative 
finding was true for both a free to use package 
(MoodGYM) and commercially produced cCBT (Beating 
the Blues). We found a significant benefit for cCBT in a 
secondary analysis for mental health quality of life and 
generic psychological wellbeing at 12 months after 
treatment. These secondary outcomes favoured the free 
to use package, but no consistent effect was seen for 
commercially produced cCBT at all but one time point 
for one outcome (mental health quality of life at 12 
months). It is questionable whether this would be seen 
as clinically important and was not observed for the pri-
mary outcome of four months nor was it evident at lon-
ger term follow-up.
To our knowledge the REEACT trial is the largest 
pragmatic independent evaluation of the effectiveness 
of supported cCBT in primary care. The trial is novel in 
that we examined a question that is important to com-
missioners of services by comparing packages that were 
table 9 | primary and secondary care services accessed by trial participants from baseline to 12 month follow-up (data 
obtained through gp medical records)
Service
Beating the Blues (n=173) usual gp care (n=202) MoodgyM (n=205)
Mean (Sd) used by (%) Mean (Sd) used by (%) Mean (Sd) used by (%)
primary care
GP 7.66 (5.48) 96 6.94 (4.82) 96 6.98 (4.62) 98
Nurse 1.60 (2.31) 58 1.86 (2.85) 63 2.03 (3.86) 61
Out of hours 0.09 (0.33) 8 0.07 (0.31) 6 0.06 (0.26) 5
Medication
Depression related NA 82 NA 84 NA 77
Secondary care
IAPT 0.25 (1.23) 5 0.41 (1.25) 13 0.33 (1.46) 7
CMHT 0.20 (1.58) 5 0.14 (0.70) 6 0.08 (0.41) 4
Counsellor 0.28 (1.65) 5 0.04 (0.29) 2 0.13 (0.86) 3
Psychiatric 0.17 (1.16) 5 0.13 (0.82) 3 0.11 (0.88) 2
Psychological 0.46 (2.95) 4 0.37 (2.26) 4 0.01 (0.21) 1
NA=not applicable; IAPT=Improving Access to Psychological Therapy (NHS service offering psychological interventions to individuals with depression 
and anxiety disorders); CMHT=community mental health teams.
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free to use versus commercially available products. 
Both these products were recommended in depression 
guidelines issued by NICE at the time we designed the 
REEACT trial and were still endorsed by NICE at the 
time of publication.5 Our main finding is therefore that 
while cCBT has been shown to be efficacious in devel-
oper led trials, it was not effective in usual NHS care 
settings. The main reason for this was low adherence 
and engagement with treatment, rather than lack of 
efficacy.
The REEACT trial included an extended follow-up to 
24 months. Neither of the supported cCBT interventions 
showed any benefit over usual GP care when all time 
points were taken into account in a repeated measures 
analysis, although there was a small but significant 
benefit for MoodGYM at 12 months’ follow-up. By 24 
months there was no statistical evidence of a difference 
between intervention and control. The small benefit for 
MoodGYM at 12 months is therefore difficult to interpret 
and is not in keeping with other research in this spe-
cialty, where benefit is usually observed only in the 
short term.33
Comparison with other studies
The results of the REEACT trial are different from those 
from developer led trials, which have recently been 
summarised in systematic reviews9 10  and technology 
appraisals.7  Aside from the independence of the REE-
ACT evaluation from those who have developed cCBT, 
there are several differences in design that are worthy 
of note. The first is that the REEACT trial was purposely 
conducted entirely within primary care, which is the 
setting in which most people with depression receive 
treatment.34 This contrasts with several trials that have 
recruited their target population through the internet 
or in specialist (secondary care) referral centres or in 
centres that have developed specialist clinics where 
participants are directly supervised while they use a 
computer package. We would argue that this enhances 
the degree to which the REEACT results can be applied 
to primary care and to mental health services led by 
primary care.
The second difference is the level of support that 
was offered. In the REEACT trial participants were pro-
actively offered a high level of technical support and 
weekly encouragement to use the computer packages, 
but we purposely did not augment structured psycho-
logical therapy over the telephone using trained psy-
chological therapists. Telephone support in the 
REEACT trial did not involve detailed explanations of 
cognitive behavioural therapy and did not involve 
detailed review of homework or tasks between ses-
sions. The cCBT was therefore a form of supported self 
help but was not one that was guided by a clinician. 
Systematic reviews have shown that unsupported self 
help treatment (including unsupported computer 
delivered self help) has minimal effects and a rela-
tively small effect size.12  35  In contrast, efficacy trials 
have shown that more intensively supported treat-
ments generally have moderate effect sizes claimed to 
be comparable with face to face therapy.11  The level of 
support in the REEACT trial is one that is at least as 
intensive as that offered in many NHS care settings 
and is in line with (or in the case of MoodGYM exceeds) 
the level of support that is generally offered.16  The 
REEACT trial therefore represents an evaluation of a 
supported intervention that replicates the use of cCBT 
in routine primary care settings. The chosen level of 
support, however, was less intense than other efficacy 
trials in which computer use has, for example, been 
supervised on a 1:1 basis by therapists or in which a 
healthcare professional has been physically present to 
ensure the user interacts successfully with the com-
puter (see, for example, Proudfoot and colleagues15 ). 
More intensively supported cCBT might have been 
more likely to have resulted in a positive outcome but 
would have diluted the pragmatic evaluation of the 
effectiveness of cCBT as it is offered in primary care. 
Because there was weekly proactive telephone sup-
port, we expected that this effectiveness trial would 
show some benefit comparable with that observed in 
developer led guided self help trials.12  Future research 
could explore whether the use of telephone delivered 
clinician support results in a higher level of engage-
ment and a more effective form of computerised treat-
ment. An alternative mode of support is by the use of 
online therapists, which has shown positive results in 
primary care.36
Our other significant finding was that, despite the 
provision of a high level of telephone support, there 
was relatively low uptake of computerised CBT. This 
finding is in line with other lower intensity forms of 
intervention for depression offered in primary care, 
where dropout and failure to engage with therapy are 
common.37  It contrasts, however, with other developer 
led efficacy trials in which good levels of engagement 
and uptake have been reported.37
Again we note that REEACT was a pragmatic study, in 
which a feasible and representative primary care inter-
vention was replicated within the context of a ran-
domised controlled trial. The trial was a real world 
evaluation of supported computer delivered CBT. The 
reasons for poor engagement and barriers to the use of 
this technology in routine care have hitherto not been 
explored within the context of trials, and a companion 
paper reports in depth the reasons for poor engage-
ment.38 We have found that participants offered cCBT 
were generally unwilling to engage with computer pro-
grammes and highlighted the difficulty in repeatedly 
logging on to computer systems when they are clinically 
depressed. Participants said they wanted a greater level 
of clinical support as an adjunct to therapy, and, in the 
absence of this support, they commonly disengaged 
with the computer programmes.
The REEACT study was also pragmatic in reflecting 
the degree to which GPs might offer cCBT for people 
with a range of severities of depression. Though we set 
a minimum entry criterion (PHQ-9 ≥10) we noted that 
the mean score was 17, which is indicative of moderately 
severe depression. This is a slightly higher level of 
severity than is recommended in NICE guidance, and an 
important finding is that GPs seem ready to offer cCBT 
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as a treatment at a range of severities. This was often in 
combination with treatment with antidepressants. 
Future research could evaluate cCBT within a more con-
strained range of severity of depression; though we 
noted that use was low for people with all severities of 
depression.
limitations of reeaCt trial
There were limitations to this study. Firstly, participants 
were selected with a definition of depression based on a 
cut point drawn from a depression severity scale.17  We 
did not use a diagnosis of depression based on a struc-
tured diagnostic interview schedule as the primary 
inclusion criterion. REEACT, however, was a pragmatic 
randomised controlled trial, and we deliberately 
adopted a criterion drawn from an instrument that is 
widely used in UK primary care to guide treatment.18 
We did, however, concurrently use a diagnostic inter-
view schedule, and 81% or our participants met the ICD 
criteria for depressive episode. Secondly, REEACT was 
powered at 80% to detect a modest effect size that is 
comparable with other low intensity forms of psycho-
logical therapy observed in primary care settings.37  We 
did not have sufficient statistical power to detect much 
smaller effect sizes that have been observed in entirely 
unsupported cCBT.35  Nevertheless, REEACT was a sup-
ported form of cCBT, and our trial exceeded 80% statis-
tical power to detect the range of effect sizes that have 
been reported in systematic reviews of previous trials of 
cCBT.12
We also note that there was potential crossover, with 
some reported access of computer based treatment or 
support by 19% participants in the usual care arm of the 
REEACT trial. Unfortunately we do no not know what 
form of support was accessed, and this could include a 
range of computer materials (including cCBT pro-
grammes). From the intervention arms, we were able to 
access the computer records to ascertain actual use of 
the technology, and this was low even for people who 
self reported accessing cCBT. As a pragmatic study, 
usual care was not constrained in REEACT, and this was 
a strength of the design. It is unlikely that crossover and 
dilution of effect is a sufficient explanation of the nega-
tive findings in REEACT, and the more likely explana-
tion is lack of uptake of the intervention when this is 
offered, even with telephone support.
Conclusions and policy implications
Computerised CBT forms a core component of psycho-
logical therapy services in primary care in the UK and 
other health systems. The overall conclusion is that 
supported computerised cognitive behaviour therapy 
confers modest or no benefit over usual GP care and 
suggests that the routine promotion and commission-
ing of cCBT be reconsidered in light of our findings. 
Commercially developed computerised cognitive 
behaviour therapy products confer little or no benefit 
over free to use products. This is an important finding 
for those who commission services and purchase com-
mercial products on behalf of publicly funded health 
services. The routine use and purchase of computerised 
therapy is likely to be an ineffective form of low inten-
sity treatment for depression and an inefficient use of 
finite healthcare resources. There is a range of treat-
ments for depression that might be considered instead 
of cCBT. These include telephone guided self help, bib-
liotherapy, low intensity psychological workers sup-
porting self help technologies, and therapist delivered 
cognitive behaviour therapy.5 There is a need to evalu-
ate the clinical and cost effectiveness of such 
approaches. In relation to cCBT there is, for example, an 
ongoing independent trial (REEACT 2) of the effective-
ness of guided computer therapy versus the effective-
ness of guided bibliotherapy for depression.
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